EB病毒阳性弥漫大B细胞淋巴瘤的治疗

doi:10.3760/cma.j.cn371439-20200923-00075

摘要/Abstract

摘要：

EB病毒(EBV)阳性弥漫大B细胞淋巴瘤(DLBCL)是与慢性EBV感染相关的一类罕见的B细胞淋巴瘤。主要为活化B细胞亚型,具有侵袭性,对联合化疗的反应较EBV阴性患者差,预后不良。随着对EBV阳性DLBCL发病机制、生物学特征的研究不断深入,新型治疗策略不断出现,如抗病毒治疗、单克隆抗体、信号通路抑制剂以及包括细胞免疫疗法和免疫检查点抑制剂在内的免疫疗法,这些新的治疗策略能够提高疗效,并减少不良反应的发生。

关键词: 疱疹病毒4型,人, 淋巴瘤,大B细胞,弥漫性, 抗体,单克隆, 免疫疗法

Abstract:

Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma (DLBCL) is a rare type of B cell lymphoma associated with chronic EBV infection. The main subtype is activated B cell-like and it's invasive. The response to combined chemotherapy is worse than that of EBV negative patients, and the prognosis is poor. As the researches on pathogenesis and biological characteristics of EBV positive DLBCL deepen, new therapeutic strategies are emerging, such as antiviral therapy, monoclonal antibody, inhibitors of signaling pathway and immunotherapy including cellular immunotherapy and immune checkpoint inhibitor. These new therapeutic strategies can improve the efficacy and reduce the occurrence of adverse reactions.

Key words: Herpesvirus 4,human, Lymphomalarge B-cell,diffuse, Antibodies,monoclonal, Immunotherapy

郭奕维, 刘爱春. EB病毒阳性弥漫大B细胞淋巴瘤的治疗[J]. 国际肿瘤学杂志, 2021, 48(7): 385-388.

Guo Yiwei, Liu Aichun. Treatment of EB virus positive diffuse large B cell lymphoma[J]. Journal of International Oncology, 2021, 48(7): 385-388.

参考文献 31

[1]	Marques-Piubelli ML, Salas YI, Pachas C, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review[J]. Pathology, 2020, 52(1):40-52. DOI: 10.1016/j.pathol.2019.09.006. doi: 10.1016/j.pathol.2019.09.006
[2]	Zhou Y, Xu Z, Lin W, et al. Comprehensive genomic profifiling of EBV-positive diffuse large B-cell lymphoma and the expression and clinicopathological correlations of some related genes[J]. Front Oncol, 2019, 9:683. DOI: 10.3389/fonc.2019.00683. doi: 10.3389/fonc.2019.00683
[3]	Amaya D, Moreno JC, Calvache N, et al. Prevalence and clinico-pathological characteristics in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma in a high complexity hospital in Cali, Columbia[J]. Rev Esp Patol, 2019, 52(3):139-146. DOI: 10.1016/j.patol.2019.01.002.
[4]	Nicolae A, Pittaluga S, Abdullah S, et al. EBV positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment[J]. Blood, 2015, 126(7):863-872. DOI: 10.1182/blood-2015-02-630632. doi: 10.1182/blood-2015-02-630632 pmid: 25999451
[5]	Keane C, Tobin J, Gunawardana J, et al. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma[J]. Eur J Haematol, 2019, 103(3):200-207. DOI: 10.1111/ejh.13274. doi: 10.1111/ejh.13274 pmid: 31211907
[6]	Okamoto A, Yanada M, Inaguma Y, et al. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients[J]. Hematol Oncol, 2017, 35(1):87-93. DOI: 10.1002/hon.2245. doi: 10.1002/hon.2245 pmid: 26177728
[7]	Witte HM, Merz H, Biersack H, et al. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-virus positive diffuse large B cell lymphoma[J]. Br J Haematol, 2020, 189(2):257-268. DOI: 10.1111/bjh.16342. doi: 10.1111/bjh.v189.2
[8]	Hong JY, Yoon DH, Suh C, et al. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?[J]. Ann Oncol, 2015, 26(3):548-555. DOI: 10.1093/annonc/mdu556. doi: 10.1093/annonc/mdu556 pmid: 25475080
[9]	Jöhrens K, Trappe RU, Lenze D, et al. Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center[J]. Leuk Lymphoma, 2016, 57(12):2791-2803. DOI: 10.3109/10428194.2016.1169406. doi: 10.3109/10428194.2016.1169406
[10]	Beltran BE, Castro D, Paredes S, et al. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diag-nosis, risk-stratification and management[J]. Am J Hematol, 2020, In press. DOI: 10.1002/ajh.25760.
[11]	Petrara MR, Giunco S, Serraino D, et al. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment[J]. Cancer Lett, 2015, 369(1):37-44. DOI: 10.1016/j.canlet.2015.08.007. doi: 10.1016/j.canlet.2015.08.007
[12]	Chen R, Allibone S, Bartlett NL, et al. Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma[J]. Onco Targets Ther, 2016, 9:2027-2034. DOI: 10.2147/OTT.S96175.
[13]	Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma[J]. Blood, 2017, 130(25):2709-2717. DOI: 10.1182/blood-2017-05-780049. doi: 10.1182/blood-2017-05-780049
[14]	Berger GK, McBride A, Lawson S, et al. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: a systematic review[J]. Crit Rev Oncol Hematol, 2017, 109:42-50. DOI: 10.1016/j.critrevonc.2016.11.009. doi: 10.1016/j.critrevonc.2016.11.009
[15]	Svoboda J, Bair SM, Landsburg DJ, et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas[J]. Haematologica, 2020, haematol. 2019. 238675. DOI: 10.3324/haematol.2019.238675.
[16]	Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression[J]. Blood, 2015, 125(9):1394-1402. DOI: 10.1182/blood-2014-09-598763. doi: 10.1182/blood-2014-09-598763 pmid: 25573987
[17]	Strunz PP, Schmalzing M, Heidemeier A, et al. Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor[J]. Leuk Lymphoma, 2019, 60(14):3573-3576. DOI: 10.1080/10428194.2019.1636981. doi: 10.1080/10428194.2019.1636981
[18]	Leonard JP, Kolibaba KS, Reeves JA, et al. Randomized phase Ⅱ study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma[J]. J Clin Oncol, 2017, 35(31):3538-3546. DOI: 10.1200/JCO.2017.73.2784. doi: 10.1200/JCO.2017.73.2784 pmid: 28862883
[19]	Liu JY, Kenney T, Butterworth L, et al. Abstract 2673: idelalisib has activity at clinically achievable drug concentrations in a subset of ABC and GCB diffuse large B-cell lymphoma and transformed follicular lymphoma cell lines[J]. Cancer Res, 2015, 75(15 Supplement):2673. DOI: 10.1158/1538-7445.AM2015-2673.
[20]	Maddocks K, Christian B, Jaglowski S, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma[J]. Blood, 2015, 125(2):242-248. DOI: 10.1182/blood-2014-08-597914. doi: 10.1182/blood-2014-08-597914 pmid: 25355819
[21]	Battle-Lopez A, Gonzalez de Villambrosia S, Nuñez J, et al. Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options[J]. Expert Rev Anticancer Ther, 2016, 16(4):411-421. DOI: 10.1586/14737140.2016.1149065. doi: 10.1586/14737140.2016.1149065
[22]	Yoon SE, Kim SJ, Yoon DH, et al. A phase Ⅱ study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis[J]. Ann Hematol, 2020, 99(6):1283-1291. DOI: 10.1007/s00277-020-04005-6. doi: 10.1007/s00277-020-04005-6
[23]	Liu L, Liu Q, Feng S. Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation[J]. Ther Adv Hematol, 2020, 11:2040620720910964. DOI: 10.1177/2040620720910964.
[24]	Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor[J]. J Clin Oncol, 2015, 33(6):540-549. DOI: 10.1200/JCO.2014.56.2025. doi: 10.1200/JCO.2014.56.2025 pmid: 25154820
[25]	He X, Xu C. Immune checkpoint signaling and cancer immunothe-rapy[J]. Cell Res, 2020, 30(8):660-669. DOI: 10.1038/s41422-020-0343-4. doi: 10.1038/s41422-020-0343-4
[26]	Sakakibara A, Kohno K, Ishikawa E, et al. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV+ lymphoproliferative diseases: new insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142[J]. Pathol Int, 2020, 70(8):481-492. DOI: 10.1111/pin.12946. doi: 10.1111/pin.12946 pmid: 32367595
[27]	Kataoka K, Miyoshi H, Sakata S, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas[J]. Leukemia, 2019, 33(7):1687-1699.DOI: 10.1038/s41375-019-0380-5. doi: 10.1038/s41375-019-0380-5
[28]	Kim SJ, Hyeon J, Cho I, et al. Comparison of efficacy of pembro-lizumab between Epstein-Barr virus positive and negative relapsed or refractory non-Hodgkin lymphomas[J]. Cancer Res Treat, 2019, 51(2):611-622. DOI: 10.4143/crt.2018.191. doi: 10.4143/crt.2018.191
[29]	Quan L, Chen X, Liu A, et al. PD-1 blockade can restore functions of T-cells in Epstein-Barr virus-positive diffuse large B-cell lymphoma in vitro[J]. PLoS One, 2015, 10(9):e0136476. DOI: 10.1371/journal.pone.0136476. doi: 10.1371/journal.pone.0136476
[30]	Abramson Cancer Center of the University of Pennsylvania. Pembro-lizumab in realpsed or refractory extranodal NK/T-cell lymphoma, nasal type and EBV-associated diffuse large B cell lymphomas[EB/OL]. ClinicalTrials.gov. (2018-07-13) [2020-08-31]. https://clinicaltrials.gov/ct2/show/NCT03586024?term=NCT0358602-4&draw=2&rank=1.
[31]	The First Affiliated Hospital with Nanjing Medical University. Sinti-limab in combination with R-CHOP in patients with treatment-naive EBV-positive DLBCL, NOS[EB/OL]. ClinicalTrials.gov. ( 2019-11-29) [2020-08-31]. https://clinicaltrials.gov/ct2/show/NCT04181489?term=NCT04181489&draw=2&rank=1.